Ask Question
   Sign Guest book
                                                        

 
About Lymphoma | Advocacy | Art | CAM & Life Style | Clinical trials | Docs | Centers | Guidelines at Diagnosis | Side Effects | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Independent of industry funding, PAL depends on your support!

tax deductible

Patients Against Lymphoma

 

Clinical Trials >  Locate by class of agent:

Monoclonal antibody | Bispecific antibody
Antibody-drug conjugates | Radioimmunotherapy | Immune mediated | Cytotoxic
 Epigenetic | BCL-2 | Kinase inhibitors | mTOR | Other

Find by lymphoma type AND treatment status  | Our Trials of Interest | About Our Trial Tools

Last update: 05/13/2013

Agent

BOLD names are
FDA approved agents

 		 B or T cell 
 		 Target
of Drug
 		 Approved
Indication
 		 Queries

Locate
Studies on
ClinicalTrials.gov

 

 Counting
 Clicks
as of
3/7/13

Total:
4,651		 Find
Clinical Reports
on Agent

Google
Scholar
 

Monoclonal antibodies (Mab)
  See also Immune mediated

Monoclonal antibodies (MAbs) are similar to antibodies produced by the body in response to infection.  MAbs bind to specific receptor expressed on the tumor and some normal cells.

 

Click agent to search for
 mechanism of action

   Target  

Find Trials
Count
 		 Clinical Reports

MEDI-551 (humanized antibody) 

B cd19 - Find trials for agent
>		  44 Reports

 
Arzerra ® (Ofatumumab)

B cd20 CLL Find trials for agent
>		 183 Reports

Rituxan ® (Rituximab / Mabthera)

B cd20 NHL Find trials for agent
>		 70 Reports

GA-101 (Obinutuzumab)

B cd20 - Find trials for agent
>		 398 Reports

Ublituximab

B cd20 -  Find trials for agent
>		 18  

Veltuzumab / Immu-106 / Ha20

B cd20 - Find trials for agent
>		 11 Reports

Epratuzumab

B cd22 - Find trials for agent
>		 84 Reports

Lumiliximab

 B cd23 - Find trials for agent
>		 40 Reports

SGN-30

 B / T cd30 - Find trials for agent
>		 53 Reports

TRU-016

B cd37 - Find trials for agent
>		 72 Reports

Zanolimumab

T cd4 - Find trials for agent
>		 53 Reports

Campath ® (alemtuzumab)

B cd52 CLL Find trials for agent
>		 33 Reports

MDX-1411

B / T cd70 - Find trials for agent
>
 		 50 Reports

Milatuzumab / hLL1

B cd74 - Find trials for agent
>		 50 Reports

IMMU-114 (anti-HLA-DR)

  HLA-DR - Find trials for agent
> 		1 Reports

Mogamulizumab
(KW-0761; AMG-761)

T CCR4 - Find trials for agent
>		 45 Reports

Bispecific antibodies

Binding two receptors expressed on tumor cells and/or other immune cells

 
    Target  

Find Trials

 Count Reports

DT2219ARL

anti-CD19/22 Bispecific antibody + immunotoxin

 B cd19 cd22 Initial
count:
 72 >		  Find trials for agent
 >
 
85

 

 Reports

Blinatumomab / MT103 / BiTe)

B cd3 cd19 - Find trials for agent
>
 		 94 Reports

antibody-drug conjugates

Uses antibodies to delivers toxins to cells that have a specific target receptor

    Target  

Find Trials

 Count Reports

SGN-CD19A
 anti-CD19 + toxin

B cd19 NEW Find trials for agent
>
 		 3 Reports

SAR3419
 anti-CD19 + maytansinoi

 B cd19 - Find trials for agent
>
 		 104 Reports

DT2219ARL
 anti-CD19 & 22 antibody + immunotoxin

B cd19 cd22 - Find trials for agent
>
 		 100 Reports

Inotuzumab Ozogamicin
anti-CD22 + calicheamicin
 

 B cd22 - Find trials for agent
>
 		 206 Reports

DCDT2980S
anti-CD22, conjugated to MMAE

B cd22 - Find trials for agent
>
 		 18 Reports

LMB-2 immunotoxin
anti-CD25 antibody + immunotoxin

B cd25 - Find trials for agent
>
 		 28 Reports

Adcetris ® 
(SGN-35 / brentuximab vedotin)
anti-cd30 + antitubulin

 B/T cd30 HL / ALCL Find trials for agent
>		 178 Reports

Technical - PK / dosing

Radio-immunotherapy

Uses antibodies to delivers radiation to cells in a targeted way

    Target  

Find Trials

 Count Reports

Bexxar ®
anti-CD20 + iodine 131
(Tositumomab, Iodine I 131)

B cd20 NHL Find trials for agent
>
 		 63 Reports

Zevalin ®
anti-CD20 + Yttrium 90
(Ibritumomab tiuxetan)

B cd20 NHL Find trials for agent
>
 		 79 Reports

epratuzumab tetraxetan
anti-CD22 with fractionated Yttrium 90 

B cd22 - Find trials for agent
>
 		 63 Reports

Immune-mediated

Immune mediated therapy assists in helping the immune system to attack the tumor.

 See also antibody agents, and radioimmunotherapy, which may also be immune-mediated

    Target  

Find Trials

 Count Reports

Anti-PD-1 antibody

pidilizumab (CT-011)
OR BMS-936558
  
(Immune checkpoint blockade)

 B PD-1 (P7) Initial
count: 195 >		 Find trials for agent
>		 272 Reports

ipilimumab

anti-CTL-A (MXD-010)

(Immune checkpoint blockade)

 B CTL-A
t-reg		 -

Find trials for agent
>
 

 15 Reports

immunocytokine therapy

composed of two immune components – antibodies and cytokines

- - - Find trials for agent
>
 		 6 Reports


Revlimid ® / Lenalidomide / CC 5013 

(Immune modulating / cereblon)

 - unknown MDS / myeloma Find trials for agent
>
 		 95 Reports

Lenalidomide AND Rituxan

- unknown + cd20 New combination Find trials for agent
 >
 		 4 Reports

Pomalidomide 

(Immune modulating)

 - unknown NEW Find trials for agent 
>
 		 5 Reports

T-cell therapy

(adoptive immunotherapy)

 B or T - - Find trials for agent 
 >
 		 14  

cd19 CAR T-cell therapy

(CAR - chimeric antigen receptor)

(adoptive immunotherapy)

B cd19 Initial
count: 148 >		 Find trials for agent
>

184
 		 Reports

About by PAL

Vaccine (idiotype) therapy

 B tumor antigen - Find trials for agent
 > 		32 Reports

Cytotoxic Agents

Damage the DNA of rapidly dividing cells, triggering apoptosis (programmed cell death)

 
    Target  

Find Trials

 Count Reports

Treanda ®

(Bendamustine)  
 

 B or T DNA NHL/CLL Find trials for agent
> 		78 Reports

Bendamustine
phase 3 trials

 B or T DNA NHL/CLL Phase 3 trials for agent
>		 25 Reports

Folotyn ® (Pralatrexate)

- DNA T-cell Find trials for agent
> 		6 Reports

Pixantrone

B DNA - Find trials for agent
>		 6

Reports

Targeted Agents

     

Epigenetic Agents

Agents that modify gene expression (by methylation or acetylation of histones and other elements) can reprogram how tumor cells behave: grow, die, or differentiate.

DNA hypo/hyper-methylation

 can reactivate tumor suppressor genes by altering methylation

Hypermethylation-associated silencing of tumor suppressor genes has been shown to occur in lymphoid/hematopoietic malignancies, disrupting many cellular pathways.1-3 Unlike genetic alterations in cancer, hypermethylation changes are potentially reversible by pharmacologic inhibition of DNA methylation.4 The cytidine analogs 5-aza-2′-deoxycytidine and 5-azacytidine are capable of reactivating tumor suppressor genes that were silenced by hypermethylation.4

    Target  

Find Trials

 Count Reports

Vidaza ®
 
(5-Azacytidine)

 B DNA hypo-methylation initial
count: 19 >
 Find trials for agent
 > 		20 Reports

HDAC inhibition

 interferes with the function of histone deacetylase - modifying gene expression    About by PAL

  
    Target  

Find Trials

 Count Reports

Abexinostat (PCI-24781)

  HDAC   Find trials for agent
> 		25 Reports
belinostat (PXD101)
T or B HDAC   Find trials for agent
>		 32 Reports
Panobinostat (LBH589)
T or B HDAC   Find trials for agent
>		 54 Reports
Romidepsin ® (Depsipeptide)
T or B HDAC Approved for T-cell lymphoma Find trials for agent
>  		21 Reports
Valproic acid
T or B HDAC AML / MDS Find trials for agent
 >		 78 Reports
Zolinza ® (Vorinostat)
T or B HDAC Approved for T-cell lymphoma Find trials for agent
> 		87 Reports

BCL-2 inhibitors

Binds to BCL-2 pathway involved in the blocking of apoptosis (programmed cell death)

  
    Target  

Find Trials

 Count Reports
Navitoclax / ABT-263 >
Discontinued due to improvement in safety with ABT-199 below
 B bcl-2
pathway		 - http://bit.ly/5fcv13 99 Reports

ABT-199 

One re-opened study

 B bcl-2
pathway		 tumor lysis syndrome reported

Find trials for agent
>

 54 Reports
Obatoclax mesylate / GX15-070)
B bcl-2
pathway		 - Find trials for agent
>		 51 Reports

mTOR

Binds the mTOR pathway that promotes survival and cell growth

  
    Target  

Find Trials

 Count Reports
CC-223

dual mTOR inhibitor (oral)
B mTOR - Find trials for agent
>		 21 Reports
Everolimus / RAD001 (oral)
B mTOR - Find trials for agent
>		 52 Reports
Temsirolimus / CCI-779 (IV)
B mTOR - Find trials for agent
>		 38 Reports

Kinase inhibitors

Inhibit transcription pathways that are overactive in cancer

  
    Target  

Find Trials

 Count Reports

AEB071 (Sotrastaurin)

subtype
of DLBCL		  Protein Kinase C Inhibitor   Find trials for agent
>		 NEW

Report
alisertib (MLN8237)
T Aurora Kinase A t-cell
lymphoma		 Find trials for agent
>		 23 Reports
 
 Enzastaurin

NOTICE: Company is pulling this agent due to disappointing results of a study

 B C-beta - Find trials for agent
 >		 25 Reports
 
GS-1101 (formerly CAL101) idelalisib
 B PI3k delta CLL and NHL Find trials for agent
>		 438 Reports

AVL-292
B Bruton's tyrosine (Btk) - Find trials for agent
>		 70 Reports

ibrutinib (PCI-32765)
  
B Bruton's tyrosine (Btk) FDA breakthrough designation Find trials for agent
>		 396 Reports

About by PAL

Other targeted agents

  
    Target  

Find Trials

 Count Reports
PD 0332991
  Cdk - Find trials for agent
>		 19 Reports
YM155
B survivin kinase - Find trials for agent
>		 61 Reports
proteasome inhibitors

MLN970 / Bortezomib /
Velcade ® , Carfilzomib,
CEP 18770 
  proteasome inhibitors - Find trials for agent
>		 10 Reports
TL32711  
  inhibitors of apoptosis   Find trials for agent
 >		 8 Reports

See also Find Clinical Trials based on Type of Lymphoma and Clinical Circumstance
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.